Neither COVID-19, nor cryopreservation, prevented allogeneic product infusion: A report from the National Marrow Donor Program
Nosha Farhadfar(University of Florida Health), Heather E. Stefanski(National Marrow Donor Program), Steven M. Devine(National Marrow Donor Program), Jeni Newman(National Marrow Donor Program), Eric T. Ndifon(National Marrow Donor Program), Meghann Cody(National Marrow Donor Program), Jason Oakes(National Marrow Donor Program), Jeffery J. Auletta(Nationwide Children's Hospital), Jacklyn Barten(National Marrow Donor Program), J. Philip Miller(University of Minnesota), Huy P. Pham(National Marrow Donor Program), Jennifer Novakovich(National Marrow Donor Program)
Cited by 10
Related Papers
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
|New England Journal of Medicine|2018|5.7k
Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma
|New England Journal of Medicine|2012|1.2k
Current Use of and Trends in Hematopoietic Cell Transplantation in the United States
|Transplantation and Cellular Therapy|2020|718
Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes
|Journal of Clinical Oncology|2017|664